<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01577706</url>
  </required_header>
  <id_info>
    <org_study_id>2012P000197</org_study_id>
    <nct_id>NCT01577706</nct_id>
  </id_info>
  <brief_title>Spectroscopic Imaging at 4T: A Drug Challenge Study</brief_title>
  <acronym>CEBRA2</acronym>
  <official_title>Spectroscopic Imaging of GABA and Glutamate/Glutamine in Healthy Volunteers at 4T: A Double Blind, Crossover Drug Challenge Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mclean Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mclean Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      An advanced technique for rapid magnetic resonance proton spectroscopic imaging (1H-MRSI)
      will be employed in a drug challenge study in healthy volunteers to spatially map and measure
      acute changes in the brain chemicals GABA, glutamate and glutamine after administration of a
      drug. Three condition will be tested in a double-blind fashion, i)depressant, ii)stimulant,
      iii)placebo. It is hypothesized that unique and reproducible spatial and directional
      metabolic response patterns will be observed, unique to each condition within the brain.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Proton magnetic resonance spectroscopy (1H MRS) is a powerful tool for assessing
      neurochemistry non-invasively in vivo. However, the primary shortcoming in most studies is
      the lack of spatial coverage afforded by the typical single-voxel design. Limits on
      participant tolerance and financial resources restrict single-voxel studies to an examination
      of one or two carefully chosen voxels per scan, thus inadequately addressing the question of
      focal vs. global pathophysiology. A secondary shortcoming is that most studies report on
      either GABA or glutamate-glutamine (Glu-Gln) due to the technically demanding
      spectral-editing techniques that must be implemented in order to resolve and quantify those
      metabolites with any accuracy.

      1H MRS imaging (MRSI) can partially overcome these limitations by providing a global picture
      of brain chemistry rather than just the focal snapshot afforded by the single-voxel design.
      However, the scan time necessary for collecting enough data for adequate spatial resolution
      and signal-to-noise, particularly if also using specialized spectral-editing techniques, is
      still too lengthy. We recently developed a method that combines Spectroscopic Imaging with
      the MEGAPRESS-based difference-editing acquisition for optimal GABA detection as well as for
      optimal detection of Glu and Gln. This MEGACSI sequence will permit us to obtain the maximum
      amount of neurochemical information in a clinically sound scan time, while using the current
      state-of-the-art MRS editing methods for optimal detection of GABA, Glu, and Gln.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    lack of enrollment
  </why_stopped>
  <start_date type="Actual">June 2013</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Left Thalamus: Percent Change in GABA Levels After an Acute Drug Challenge</measure>
    <time_frame>from 45 minutes post-dose to 102 minutes post-dose in 19-minute intervals (4 time points at t1: 45, t2: 64, t3: 83, t4: 102 minutes post-dose)</time_frame>
    <description>The primary goal of this study is to assess the efficacy of an advanced spectroscopic imaging protocol in detecting changes in the levels of brain GABA in response to an acute drug challenge.
GABA levels are expressed as a ratio to total creatinine: GABA/Cr percent change = 100*(later timepoint - earlier timepoint) / earlier timepoint</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Left Basal-Ganglia: Percent Change in GABA Levels After an Acute Drug Challenge</measure>
    <time_frame>from 45 minutes post-dose to 102 minutes post-dose in 19-minute intervals (4 time points at t1: 45, t2: 64, t3: 83, t4: 102 minutes post-dose)</time_frame>
    <description>The primary goal of this study is to assess the efficacy of an advanced spectroscopic imaging protocol in detecting changes in the levels of brain GABA in response to an acute drug challenge.
GABA levels are expressed as a ratio to total creatinine: GABA/Cr percent change = 100*(later timepoint - earlier timepoint) / earlier timepoint</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Left Temporal: Percent Change in GABA Levels After an Acute Drug Challenge</measure>
    <time_frame>from 45 minutes post-dose to 102 minutes post-dose in 19-minute intervals (4 time points at t1: 45, t2: 64, t3: 83, t4: 102 minutes post-dose)</time_frame>
    <description>The primary goal of this study is to assess the efficacy of an advanced spectroscopic imaging protocol in detecting changes in the levels of brain GABA in response to an acute drug challenge.
GABA levels are expressed as a ratio to total creatinine: GABA/Cr percent change = 100*(later timepoint - earlier timepoint) / earlier timepoint</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Parieto-Occipital: Percent Change in GABA Levels After an Acute Drug Challenge</measure>
    <time_frame>from 45 minutes post-dose to 102 minutes post-dose in 19-minute intervals (4 time points at t1: 45, t2: 64, t3: 83, t4: 102 minutes post-dose)</time_frame>
    <description>The primary goal of this study is to assess the efficacy of an advanced spectroscopic imaging protocol in detecting changes in the levels of brain GABA in response to an acute drug challenge.
GABA levels are expressed as a ratio to total creatinine: GABA/Cr percent change = 100*(later timepoint - earlier timepoint) / earlier timepoint</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Right Thalamus: Percent Change in GABA Levels After an Acute Drug Challenge</measure>
    <time_frame>from 45 minutes post-dose to 102 minutes post-dose in 19-minute intervals (4 time points at t1: 45, t2: 64, t3: 83, t4: 102 minutes post-dose)</time_frame>
    <description>The primary goal of this study is to assess the efficacy of an advanced spectroscopic imaging protocol in detecting changes in the levels of brain GABA in response to an acute drug challenge.
GABA levels are expressed as a ratio to total creatinine: GABA/Cr percent change = 100*(later timepoint - earlier timepoint) / earlier timepoint</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Right Basal-Ganglia: Percent Change in GABA Levels After an Acute Drug Challenge</measure>
    <time_frame>from 45 minutes post-dose to 102 minutes post-dose in 19-minute intervals (4 time points at t1: 45, t2: 64, t3: 83, t4: 102 minutes post-dose)</time_frame>
    <description>The primary goal of this study is to assess the efficacy of an advanced spectroscopic imaging protocol in detecting changes in the levels of brain GABA in response to an acute drug challenge.
GABA levels are expressed as a ratio to total creatinine: GABA/Cr percent change = 100*(later timepoint - earlier timepoint) / earlier timepoint</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Right Temporal: Percent Change in GABA Levels After an Acute Drug Challenge</measure>
    <time_frame>from 45 minutes post-dose to 102 minutes post-dose in 19-minute intervals (4 time points at t1: 45, t2: 64, t3: 83, t4: 102 minutes post-dose)</time_frame>
    <description>The primary goal of this study is to assess the efficacy of an advanced spectroscopic imaging protocol in detecting changes in the levels of brain GABA in response to an acute drug challenge.
GABA levels are expressed as a ratio to total creatinine: GABA/Cr percent change = 100*(later timepoint - earlier timepoint) / earlier timepoint</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">7</enrollment>
  <condition>AOD Effects and Consequences</condition>
  <arm_group>
    <arm_group_label>Alprazolam (A)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Alprazolam (Xanax), gel-capsule, 1mg, single-dose, 1-day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dextroamphetamine (D)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Dextroamphetamine (Dexedrine), gel-capsule, 20mg, single-dose, 1-day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo (P)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo gel-capsule, single-dose, 1-day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Alprazolam</intervention_name>
    <description>Alprazolam, gel-capsule, 1mg, single-dose, 1-day</description>
    <arm_group_label>Alprazolam (A)</arm_group_label>
    <other_name>Xanax</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dextroamphetamine</intervention_name>
    <description>Dextroamphetamine, gel-capsule, 20mg, single-dose, 1-day</description>
    <arm_group_label>Dextroamphetamine (D)</arm_group_label>
    <other_name>Dexedrine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo, gel-capsule, single-dose, 1-day</description>
    <arm_group_label>Placebo (P)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participants will be male volunteers between the ages of 21-45

          -  Non-smoking participants are preferred, but will admit those who smoke less than 5
             cigarettes per day

          -  Participants must be able to read screening materials including consent form and give
             informed consent

        Exclusion Criteria:

          -  Participants cannot meet DSM-IV criteria for lifetime and/or current mood, anxiety,
             psychotic, and alcohol/drug use disorders as identified by the SCID

          -  Participants cannot be taking any prescription medication (except oral contraceptives,
             certain short-term anti-fungal agents, and some topical creams for dermal conditions)
             or nutritional supplements

          -  Participants cannot be taking any psychotropic medications

          -  Participants cannot have a history of major head trauma resulting in cognitive
             impairment, seizure, or other neurological disorders.

          -  Participants cannot have any conditions that are contraindicated for MRI

          -  Participants cannot have a family history of alcoholism

          -  Participants cannot have any abnormal blood chemistries/urinalysis results or any
             other medical condition that may affect drug disposition (e.g., Hepatitis C)

          -  Participants cannot have current or past cardiac problems, and they also cannot have a
             family history of sudden death or ventricular arrhythmia

          -  Participants who, in the investigators' judgment, will not likely be able to comply
             with the study protocol.

          -  Participants cannot have any clinically significant findings in the structural
             anatomic brain scans (per the MRI report read by a board-certified radiologist).
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John E Jensen, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mclean Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>McLean Imaging Center, McLean Hospital</name>
      <address>
        <city>Belmont</city>
        <state>Massachusetts</state>
        <zip>02478-9106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 11, 2012</study_first_submitted>
  <study_first_submitted_qc>April 13, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 16, 2012</study_first_posted>
  <results_first_submitted>September 25, 2014</results_first_submitted>
  <results_first_submitted_qc>March 24, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">April 4, 2017</results_first_posted>
  <last_update_submitted>March 24, 2017</last_update_submitted>
  <last_update_submitted_qc>March 24, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 4, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mclean Hospital</investigator_affiliation>
    <investigator_full_name>John Eric Nestler Jensen</investigator_full_name>
    <investigator_title>Associate Biophysicist, Director-High Field Imaging and Spectroscopy Program</investigator_title>
  </responsible_party>
  <keyword>GABA</keyword>
  <keyword>glutamate</keyword>
  <keyword>glutamine</keyword>
  <keyword>spectroscopy</keyword>
  <keyword>brain</keyword>
  <keyword>imaging</keyword>
  <keyword>alprazolam</keyword>
  <keyword>dextroamphetamine</keyword>
  <keyword>placebo</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alprazolam</mesh_term>
    <mesh_term>Dextroamphetamine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>At present, there is no plan to share IPD data.</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Dextroamphetamine, Alprazolam, Placebo Sequence</title>
          <description>Healthy male volunteers receiving drug and undergoing 1H-MRSI scanning
Alprazolam: Alprazolam, gel-capsule, 1mg, single-dose, 1-day Dextroamphetamine: Dextroamphetamine, gel-capsule, 20mg, single-dose, 1-day
Placebo: single-dose, 1-day</description>
        </group>
        <group group_id="P2">
          <title>Alprazolam, Dextroamphetamine, Placebo Sequence</title>
          <description>Healthy male volunteers receiving drug and undergoing 1H-MRSI scanning
Alprazolam: Alprazolam, gel-capsule, 1mg, single-dose, 1-day Dextroamphetamine: Dextroamphetamine, gel-capsule, 20mg, single-dose, 1-day
Placebo: single-dose, 1-day</description>
        </group>
        <group group_id="P3">
          <title>Placebo, Dextroamphetamine, Alprazolam Sequence</title>
          <description>Healthy male volunteers receiving drug and undergoing 1H-MRSI scanning
Alprazolam: Alprazolam, gel-capsule, 1mg, single-dose, 1-day Dextroamphetamine: Dextroamphetamine, gel-capsule, 20mg, single-dose, 1-day
Placebo: single-dose, 1-day</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>First Intervention (1 Day)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Washout (at Least 1 Week)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Second Intervention (1 Day)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Washout (at Least 1 Week)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Third Intervention (1 Day)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Healthy male volunteers receiving drug and undergoing 1H-MRSI scanning</population>
      <group_list>
        <group group_id="B1">
          <title>All Study Participants</title>
          <description>Healthy male volunteers receiving drug and undergoing 1H-MRSI scanning
Alprazolam: Alprazolam, gel-capsule, 1mg, single-dose, 1-day
Dextroamphetamine: Dextroamphetamine, gel-capsule, 20mg, single-dose, 1-day</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="7"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28.9" spread="7.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Left Thalamus: Percent Change in GABA Levels After an Acute Drug Challenge</title>
        <description>The primary goal of this study is to assess the efficacy of an advanced spectroscopic imaging protocol in detecting changes in the levels of brain GABA in response to an acute drug challenge.
GABA levels are expressed as a ratio to total creatinine: GABA/Cr percent change = 100*(later timepoint - earlier timepoint) / earlier timepoint</description>
        <time_frame>from 45 minutes post-dose to 102 minutes post-dose in 19-minute intervals (4 time points at t1: 45, t2: 64, t3: 83, t4: 102 minutes post-dose)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Healthy male volunteers receiving drug and undergoing 1H-MRSI scanning
Placebo: single-dose, 1-day</description>
          </group>
          <group group_id="O2">
            <title>Alprazolam</title>
            <description>Healthy male volunteers receiving drug and undergoing 1H-MRSI scanning
Alprazolam: Alprazolam, gel-capsule, 1mg, single-dose, 1-day</description>
          </group>
          <group group_id="O3">
            <title>Dextroamphetamine</title>
            <description>Healthy male volunteers receiving drug and undergoing 1H-MRSI scanning
Dextroamphetamine: Dextroamphetamine, gel-capsule, 20mg, single-dose, 1-day</description>
          </group>
        </group_list>
        <measure>
          <title>Left Thalamus: Percent Change in GABA Levels After an Acute Drug Challenge</title>
          <description>The primary goal of this study is to assess the efficacy of an advanced spectroscopic imaging protocol in detecting changes in the levels of brain GABA in response to an acute drug challenge.
GABA levels are expressed as a ratio to total creatinine: GABA/Cr percent change = 100*(later timepoint - earlier timepoint) / earlier timepoint</description>
          <units>percent change</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>t1 to t2: 45min-64min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.80" lower_limit="-21.48" upper_limit="16.18"/>
                    <measurement group_id="O2" value="23.57" lower_limit="-1.97" upper_limit="64.94"/>
                    <measurement group_id="O3" value="-12.51" lower_limit="-21.04" upper_limit="21.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>t1 to t3: 45min-83min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.63" lower_limit="-7.82" upper_limit="16.87"/>
                    <measurement group_id="O2" value="39.29" lower_limit="29.17" upper_limit="50.69"/>
                    <measurement group_id="O3" value="8.26" lower_limit="-8.12" upper_limit="46.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>t1 to t4: 45min-102min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.01" lower_limit="-25.15" upper_limit="25.52"/>
                    <measurement group_id="O2" value="23.30" lower_limit="17.75" upper_limit="58.61"/>
                    <measurement group_id="O3" value="13.63" lower_limit="-1.96" upper_limit="44.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>t2 to t3: 64min-83min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.47" lower_limit="-16.73" upper_limit="52.66"/>
                    <measurement group_id="O2" value="12.72" lower_limit="1.46" upper_limit="37.76"/>
                    <measurement group_id="O3" value="17.75" lower_limit="5.02" upper_limit="30.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>t3 to t4: 83min-102min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.32" lower_limit="-20.28" upper_limit="32.66"/>
                    <measurement group_id="O2" value="-2.10" lower_limit="-10.90" upper_limit="9.20"/>
                    <measurement group_id="O3" value="5.45" lower_limit="-22.42" upper_limit="25.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>t2 to t4: 64min-102min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.44" lower_limit="-16.72" upper_limit="47.92"/>
                    <measurement group_id="O2" value="10.79" lower_limit="-4.71" upper_limit="44.32"/>
                    <measurement group_id="O3" value="24.16" lower_limit="-0.26" upper_limit="38.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Left Basal-Ganglia: Percent Change in GABA Levels After an Acute Drug Challenge</title>
        <description>The primary goal of this study is to assess the efficacy of an advanced spectroscopic imaging protocol in detecting changes in the levels of brain GABA in response to an acute drug challenge.
GABA levels are expressed as a ratio to total creatinine: GABA/Cr percent change = 100*(later timepoint - earlier timepoint) / earlier timepoint</description>
        <time_frame>from 45 minutes post-dose to 102 minutes post-dose in 19-minute intervals (4 time points at t1: 45, t2: 64, t3: 83, t4: 102 minutes post-dose)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Healthy male volunteers receiving drug and undergoing 1H-MRSI scanning
Placebo: single-dose, 1-day</description>
          </group>
          <group group_id="O2">
            <title>Alprazolam</title>
            <description>Healthy male volunteers receiving drug and undergoing 1H-MRSI scanning
Alprazolam: Alprazolam, gel-capsule, 1mg, single-dose, 1-day</description>
          </group>
          <group group_id="O3">
            <title>Dextroamphetamine</title>
            <description>Healthy male volunteers receiving drug and undergoing 1H-MRSI scanning
Dextroamphetamine: Dextroamphetamine, gel-capsule, 20mg, single-dose, 1-day</description>
          </group>
        </group_list>
        <measure>
          <title>Left Basal-Ganglia: Percent Change in GABA Levels After an Acute Drug Challenge</title>
          <description>The primary goal of this study is to assess the efficacy of an advanced spectroscopic imaging protocol in detecting changes in the levels of brain GABA in response to an acute drug challenge.
GABA levels are expressed as a ratio to total creatinine: GABA/Cr percent change = 100*(later timepoint - earlier timepoint) / earlier timepoint</description>
          <units>percent change</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>t1 to t2: 45min-64min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.91" lower_limit="-32.57" upper_limit="40.70"/>
                    <measurement group_id="O2" value="43.17" lower_limit="12.28" upper_limit="47.33"/>
                    <measurement group_id="O3" value="5.28" lower_limit="-6.26" upper_limit="39.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>t1 to t3: 45min-83min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.11" lower_limit="-12.57" upper_limit="24.86"/>
                    <measurement group_id="O2" value="43.09" lower_limit="0.95" upper_limit="121.66"/>
                    <measurement group_id="O3" value="17.06" lower_limit="-8.04" upper_limit="58.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>t1 to t4: 45min-102min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.59" lower_limit="-24.01" upper_limit="47.89"/>
                    <measurement group_id="O2" value="44.26" lower_limit="26.85" upper_limit="57.43"/>
                    <measurement group_id="O3" value="14.68" lower_limit="-24.68" upper_limit="80.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>t2 to t3: 64min-83min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.58" lower_limit="-31.51" upper_limit="49.01"/>
                    <measurement group_id="O2" value="6.57" lower_limit="-7.83" upper_limit="35.21"/>
                    <measurement group_id="O3" value="13.40" lower_limit="-1.90" upper_limit="14.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>t3 to t4: 83min-102min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.66" lower_limit="-23.72" upper_limit="99.09"/>
                    <measurement group_id="O2" value="3.53" lower_limit="-30.30" upper_limit="42.90"/>
                    <measurement group_id="O3" value="20.19" lower_limit="-32.47" upper_limit="47.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>t2 to t4: 64min-102min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.10" lower_limit="-21.73" upper_limit="45.14"/>
                    <measurement group_id="O2" value="-4.57" lower_limit="-25.72" upper_limit="28.48"/>
                    <measurement group_id="O3" value="22.34" lower_limit="3.56" upper_limit="32.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Left Temporal: Percent Change in GABA Levels After an Acute Drug Challenge</title>
        <description>The primary goal of this study is to assess the efficacy of an advanced spectroscopic imaging protocol in detecting changes in the levels of brain GABA in response to an acute drug challenge.
GABA levels are expressed as a ratio to total creatinine: GABA/Cr percent change = 100*(later timepoint - earlier timepoint) / earlier timepoint</description>
        <time_frame>from 45 minutes post-dose to 102 minutes post-dose in 19-minute intervals (4 time points at t1: 45, t2: 64, t3: 83, t4: 102 minutes post-dose)</time_frame>
        <population>One participant is missing GABA level at t4 while on Placebo, and one participant is missing GABA level at t2 while on Alprazolam.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Healthy male volunteers receiving drug and undergoing 1H-MRSI scanning
Placebo: single-dose, 1-day</description>
          </group>
          <group group_id="O2">
            <title>Alprazolam</title>
            <description>Healthy male volunteers receiving drug and undergoing 1H-MRSI scanning
Alprazolam: Alprazolam, gel-capsule, 1mg, single-dose, 1-day</description>
          </group>
          <group group_id="O3">
            <title>Dextroamphetamine</title>
            <description>Healthy male volunteers receiving drug and undergoing 1H-MRSI scanning
Dextroamphetamine: Dextroamphetamine, gel-capsule, 20mg, single-dose, 1-day</description>
          </group>
        </group_list>
        <measure>
          <title>Left Temporal: Percent Change in GABA Levels After an Acute Drug Challenge</title>
          <description>The primary goal of this study is to assess the efficacy of an advanced spectroscopic imaging protocol in detecting changes in the levels of brain GABA in response to an acute drug challenge.
GABA levels are expressed as a ratio to total creatinine: GABA/Cr percent change = 100*(later timepoint - earlier timepoint) / earlier timepoint</description>
          <population>One participant is missing GABA level at t4 while on Placebo, and one participant is missing GABA level at t2 while on Alprazolam.</population>
          <units>percent change</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>t1 to t2: 45min-64min</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.24" lower_limit="-30.56" upper_limit="97.99"/>
                    <measurement group_id="O2" value="4.38" lower_limit="-22.54" upper_limit="60.19"/>
                    <measurement group_id="O3" value="6.36" lower_limit="-9.12" upper_limit="58.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>t1 to t3: 45min-83min</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.82" lower_limit="-61.55" upper_limit="-10.61"/>
                    <measurement group_id="O2" value="13.44" lower_limit="-18.74" upper_limit="56.65"/>
                    <measurement group_id="O3" value="1.34" lower_limit="-12.22" upper_limit="15.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>t1 to t4: 45min-102min</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.77" lower_limit="-17.82" upper_limit="7.78"/>
                    <measurement group_id="O2" value="58.49" lower_limit="-56.01" upper_limit="98.58"/>
                    <measurement group_id="O3" value="18.24" lower_limit="-15.13" upper_limit="31.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>t2 to t3: 64min-83min</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.55" lower_limit="-34.46" upper_limit="24.10"/>
                    <measurement group_id="O2" value="14.55" lower_limit="-2.21" upper_limit="48.14"/>
                    <measurement group_id="O3" value="-6.70" lower_limit="-27.30" upper_limit="15.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>t3 to t4: 83min-102min</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.83" lower_limit="-4.64" upper_limit="55.05"/>
                    <measurement group_id="O2" value="32.81" lower_limit="-45.86" upper_limit="44.54"/>
                    <measurement group_id="O3" value="7.53" lower_limit="-20.13" upper_limit="29.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>t2 to t4: 64min-102min</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.03" lower_limit="-40.16" upper_limit="1.63"/>
                    <measurement group_id="O2" value="19.68" lower_limit="-43.21" upper_limit="54.55"/>
                    <measurement group_id="O3" value="-20.20" lower_limit="-26.64" upper_limit="15.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Parieto-Occipital: Percent Change in GABA Levels After an Acute Drug Challenge</title>
        <description>The primary goal of this study is to assess the efficacy of an advanced spectroscopic imaging protocol in detecting changes in the levels of brain GABA in response to an acute drug challenge.
GABA levels are expressed as a ratio to total creatinine: GABA/Cr percent change = 100*(later timepoint - earlier timepoint) / earlier timepoint</description>
        <time_frame>from 45 minutes post-dose to 102 minutes post-dose in 19-minute intervals (4 time points at t1: 45, t2: 64, t3: 83, t4: 102 minutes post-dose)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Healthy male volunteers receiving drug and undergoing 1H-MRSI scanning
Placebo: single-dose, 1-day</description>
          </group>
          <group group_id="O2">
            <title>Alprazolam</title>
            <description>Healthy male volunteers receiving drug and undergoing 1H-MRSI scanning
Alprazolam: Alprazolam, gel-capsule, 1mg, single-dose, 1-day</description>
          </group>
          <group group_id="O3">
            <title>Dextroamphetamine</title>
            <description>Healthy male volunteers receiving drug and undergoing 1H-MRSI scanning
Dextroamphetamine: Dextroamphetamine, gel-capsule, 20mg, single-dose, 1-day</description>
          </group>
        </group_list>
        <measure>
          <title>Parieto-Occipital: Percent Change in GABA Levels After an Acute Drug Challenge</title>
          <description>The primary goal of this study is to assess the efficacy of an advanced spectroscopic imaging protocol in detecting changes in the levels of brain GABA in response to an acute drug challenge.
GABA levels are expressed as a ratio to total creatinine: GABA/Cr percent change = 100*(later timepoint - earlier timepoint) / earlier timepoint</description>
          <units>percent change</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>t1 to t2: 45min-64min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.09" lower_limit="-14.53" upper_limit="23.67"/>
                    <measurement group_id="O2" value="-0.51" lower_limit="-26.89" upper_limit="22.96"/>
                    <measurement group_id="O3" value="39.69" lower_limit="-12.79" upper_limit="47.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>t1 to t3: 45min-83min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.60" lower_limit="-13.79" upper_limit="21.08"/>
                    <measurement group_id="O2" value="1.90" lower_limit="-4.50" upper_limit="13.63"/>
                    <measurement group_id="O3" value="-10.29" lower_limit="-21.14" upper_limit="21.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>t1 to t4: 45min-102min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.54" lower_limit="-1.31" upper_limit="59.63"/>
                    <measurement group_id="O2" value="21.95" lower_limit="5.90" upper_limit="41.00"/>
                    <measurement group_id="O3" value="22.35" lower_limit="1.00" upper_limit="56.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>t2 to t3: 64min-83min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.15" lower_limit="-20.41" upper_limit="30.46"/>
                    <measurement group_id="O2" value="4.64" lower_limit="-7.82" upper_limit="37.25"/>
                    <measurement group_id="O3" value="-17.33" lower_limit="-41.00" upper_limit="2.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>t3 to t4: 83min-102min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.76" lower_limit="15.07" upper_limit="33.23"/>
                    <measurement group_id="O2" value="10.78" lower_limit="-8.66" upper_limit="33.39"/>
                    <measurement group_id="O3" value="36.38" lower_limit="19.58" upper_limit="65.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>t2 to t4: 64min-102min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.46" lower_limit="3.73" upper_limit="50.47"/>
                    <measurement group_id="O2" value="18.83" lower_limit="3.59" upper_limit="41.72"/>
                    <measurement group_id="O3" value="7.97" lower_limit="-19.53" upper_limit="26.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Right Thalamus: Percent Change in GABA Levels After an Acute Drug Challenge</title>
        <description>The primary goal of this study is to assess the efficacy of an advanced spectroscopic imaging protocol in detecting changes in the levels of brain GABA in response to an acute drug challenge.
GABA levels are expressed as a ratio to total creatinine: GABA/Cr percent change = 100*(later timepoint - earlier timepoint) / earlier timepoint</description>
        <time_frame>from 45 minutes post-dose to 102 minutes post-dose in 19-minute intervals (4 time points at t1: 45, t2: 64, t3: 83, t4: 102 minutes post-dose)</time_frame>
        <population>One participant ismissing GABA level at t4 while on Dextroamphetamine</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Healthy male volunteers receiving drug and undergoing 1H-MRSI scanning
Placebo: single-dose, 1-day</description>
          </group>
          <group group_id="O2">
            <title>Alprazolam</title>
            <description>Healthy male volunteers receiving drug and undergoing 1H-MRSI scanning
Alprazolam: Alprazolam, gel-capsule, 1mg, single-dose, 1-day</description>
          </group>
          <group group_id="O3">
            <title>Dextroamphetamine</title>
            <description>Healthy male volunteers receiving drug and undergoing 1H-MRSI scanning
Dextroamphetamine: Dextroamphetamine, gel-capsule, 20mg, single-dose, 1-day</description>
          </group>
        </group_list>
        <measure>
          <title>Right Thalamus: Percent Change in GABA Levels After an Acute Drug Challenge</title>
          <description>The primary goal of this study is to assess the efficacy of an advanced spectroscopic imaging protocol in detecting changes in the levels of brain GABA in response to an acute drug challenge.
GABA levels are expressed as a ratio to total creatinine: GABA/Cr percent change = 100*(later timepoint - earlier timepoint) / earlier timepoint</description>
          <population>One participant ismissing GABA level at t4 while on Dextroamphetamine</population>
          <units>percent change</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>t1 to t2: 45min-64min</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.55" lower_limit="-6.15" upper_limit="44.75"/>
                    <measurement group_id="O2" value="2.72" lower_limit="-9.20" upper_limit="8.24"/>
                    <measurement group_id="O3" value="-3.61" lower_limit="-28.40" upper_limit="20.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>t1 to t3: 45min-83min</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.26" lower_limit="3.35" upper_limit="19.28"/>
                    <measurement group_id="O2" value="19.20" lower_limit="0.03" upper_limit="26.12"/>
                    <measurement group_id="O3" value="14.63" lower_limit="-15.89" upper_limit="33.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>t1 to t4: 45min-102min</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.39" lower_limit="-14.79" upper_limit="56.45"/>
                    <measurement group_id="O2" value="4.54" lower_limit="-9.90" upper_limit="25.80"/>
                    <measurement group_id="O3" value="30.23" lower_limit="20.15" upper_limit="43.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>t2 to t3: 64min-83min</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.13" lower_limit="-16.64" upper_limit="10.54"/>
                    <measurement group_id="O2" value="16.51" lower_limit="7.97" upper_limit="35.51"/>
                    <measurement group_id="O3" value="14.95" lower_limit="-13.80" upper_limit="33.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>t3 to t4: 83min-102min</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.87" lower_limit="-17.56" upper_limit="31.88"/>
                    <measurement group_id="O2" value="-1.78" lower_limit="-24.21" upper_limit="1.69"/>
                    <measurement group_id="O3" value="1.60" lower_limit="-15.84" upper_limit="4.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>t2 to t4: 64min-102min</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.69" lower_limit="-9.21" upper_limit="13.71"/>
                    <measurement group_id="O2" value="12.12" lower_limit="-11.69" upper_limit="38.55"/>
                    <measurement group_id="O3" value="15.51" lower_limit="10.05" upper_limit="24.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Right Basal-Ganglia: Percent Change in GABA Levels After an Acute Drug Challenge</title>
        <description>The primary goal of this study is to assess the efficacy of an advanced spectroscopic imaging protocol in detecting changes in the levels of brain GABA in response to an acute drug challenge.
GABA levels are expressed as a ratio to total creatinine: GABA/Cr percent change = 100*(later timepoint - earlier timepoint) / earlier timepoint</description>
        <time_frame>from 45 minutes post-dose to 102 minutes post-dose in 19-minute intervals (4 time points at t1: 45, t2: 64, t3: 83, t4: 102 minutes post-dose)</time_frame>
        <population>One participant is missing GABA level at t4 while on Dextroamphetamine.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Healthy male volunteers receiving drug and undergoing 1H-MRSI scanning
Placebo: single-dose, 1-day</description>
          </group>
          <group group_id="O2">
            <title>Alprazolam</title>
            <description>Healthy male volunteers receiving drug and undergoing 1H-MRSI scanning
Alprazolam: Alprazolam, gel-capsule, 1mg, single-dose, 1-day</description>
          </group>
          <group group_id="O3">
            <title>Dextroamphetamine</title>
            <description>Healthy male volunteers receiving drug and undergoing 1H-MRSI scanning
Dextroamphetamine: Dextroamphetamine, gel-capsule, 20mg, single-dose, 1-day</description>
          </group>
        </group_list>
        <measure>
          <title>Right Basal-Ganglia: Percent Change in GABA Levels After an Acute Drug Challenge</title>
          <description>The primary goal of this study is to assess the efficacy of an advanced spectroscopic imaging protocol in detecting changes in the levels of brain GABA in response to an acute drug challenge.
GABA levels are expressed as a ratio to total creatinine: GABA/Cr percent change = 100*(later timepoint - earlier timepoint) / earlier timepoint</description>
          <population>One participant is missing GABA level at t4 while on Dextroamphetamine.</population>
          <units>percent change</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>t1 to t2: 45min-64min</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.63" lower_limit="-13.56" upper_limit="32.90"/>
                    <measurement group_id="O2" value="-9.44" lower_limit="-33.69" upper_limit="-1.73"/>
                    <measurement group_id="O3" value="38.78" lower_limit="-20.68" upper_limit="69.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>t1 to t3: 45min-83min</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.97" lower_limit="-27.05" upper_limit="21.12"/>
                    <measurement group_id="O2" value="3.03" lower_limit="-19.95" upper_limit="34.72"/>
                    <measurement group_id="O3" value="67.41" lower_limit="4.27" upper_limit="106.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>t1 to t4: 45min-102min</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.53" lower_limit="-18.69" upper_limit="146.90"/>
                    <measurement group_id="O2" value="33.58" lower_limit="-7.07" upper_limit="35.39"/>
                    <measurement group_id="O3" value="37.92" lower_limit="-34.20" upper_limit="69.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>t2 to t3: 64min-83min</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.88" lower_limit="-23.90" upper_limit="1.50"/>
                    <measurement group_id="O2" value="17.08" lower_limit="4.36" upper_limit="37.09"/>
                    <measurement group_id="O3" value="21.02" lower_limit="-23.89" upper_limit="43.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>t3 to t4: 83min-102min</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.46" lower_limit="-18.70" upper_limit="178.53"/>
                    <measurement group_id="O2" value="-0.82" lower_limit="-9.81" upper_limit="37.07"/>
                    <measurement group_id="O3" value="-5.96" lower_limit="-20.03" upper_limit="1.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>t2 to t4: 64min-102min</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.15" lower_limit="-7.73" upper_limit="64.39"/>
                    <measurement group_id="O2" value="35.96" lower_limit="5.21" upper_limit="47.50"/>
                    <measurement group_id="O3" value="14.20" lower_limit="-3.22" upper_limit="37.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Right Temporal: Percent Change in GABA Levels After an Acute Drug Challenge</title>
        <description>The primary goal of this study is to assess the efficacy of an advanced spectroscopic imaging protocol in detecting changes in the levels of brain GABA in response to an acute drug challenge.
GABA levels are expressed as a ratio to total creatinine: GABA/Cr percent change = 100*(later timepoint - earlier timepoint) / earlier timepoint</description>
        <time_frame>from 45 minutes post-dose to 102 minutes post-dose in 19-minute intervals (4 time points at t1: 45, t2: 64, t3: 83, t4: 102 minutes post-dose)</time_frame>
        <population>One participant is missing GABA level at t4 while on Dextroamphetamine. Another participant is missing GABA levels both at t2 and t4 while on Dextroamphetamine. Another participant is missing GABA levels at both t2 and t4 while on Alprazolam.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Healthy male volunteers receiving drug and undergoing 1H-MRSI scanning
Placebo: single-dose, 1-day</description>
          </group>
          <group group_id="O2">
            <title>Alprazolam</title>
            <description>Healthy male volunteers receiving drug and undergoing 1H-MRSI scanning
Alprazolam: Alprazolam, gel-capsule, 1mg, single-dose, 1-day</description>
          </group>
          <group group_id="O3">
            <title>Dextroamphetamine</title>
            <description>Healthy male volunteers receiving drug and undergoing 1H-MRSI scanning
Dextroamphetamine: Dextroamphetamine, gel-capsule, 20mg, single-dose, 1-day</description>
          </group>
        </group_list>
        <measure>
          <title>Right Temporal: Percent Change in GABA Levels After an Acute Drug Challenge</title>
          <description>The primary goal of this study is to assess the efficacy of an advanced spectroscopic imaging protocol in detecting changes in the levels of brain GABA in response to an acute drug challenge.
GABA levels are expressed as a ratio to total creatinine: GABA/Cr percent change = 100*(later timepoint - earlier timepoint) / earlier timepoint</description>
          <population>One participant is missing GABA level at t4 while on Dextroamphetamine. Another participant is missing GABA levels both at t2 and t4 while on Dextroamphetamine. Another participant is missing GABA levels at both t2 and t4 while on Alprazolam.</population>
          <units>percent change</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>t1 to t2: 45min-64min</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.93" lower_limit="-18.14" upper_limit="48.46"/>
                    <measurement group_id="O2" value="-1.45" lower_limit="-19.95" upper_limit="4.29"/>
                    <measurement group_id="O3" value="2.09" lower_limit="-44.68" upper_limit="40.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>t1 to t3: 45min-83min</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.26" lower_limit="-29.56" upper_limit="62.94"/>
                    <measurement group_id="O2" value="24.29" lower_limit="-57.06" upper_limit="49.03"/>
                    <measurement group_id="O3" value="-23.17" lower_limit="-92.17" upper_limit="39.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>t1 to t4: 45min-102min</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.95" lower_limit="5.69" upper_limit="91.43"/>
                    <measurement group_id="O2" value="31.06" lower_limit="-10.94" upper_limit="62.58"/>
                    <measurement group_id="O3" value="30.23" lower_limit="-48.74" upper_limit="88.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>t2 to t3: 64min-83min</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.91" lower_limit="-39.87" upper_limit="21.80"/>
                    <measurement group_id="O2" value="-4.86" lower_limit="-16.41" upper_limit="22.82"/>
                    <measurement group_id="O3" value="18.52" lower_limit="-9.25" upper_limit="42.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>t3 to t4: 83min-102min</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.85" lower_limit="2.85" upper_limit="50.03"/>
                    <measurement group_id="O2" value="23.34" lower_limit="9.10" upper_limit="44.14"/>
                    <measurement group_id="O3" value="70.88" lower_limit="9.16" upper_limit="81.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>t2 to t4: 64min-102min</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.78" lower_limit="-31.32" upper_limit="66.56"/>
                    <measurement group_id="O2" value="19.53" lower_limit="2.75" upper_limit="52.00"/>
                    <measurement group_id="O3" value="31.58" lower_limit="-7.14" upper_limit="122.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were monitored throughout the entire clinical study which (including a no-cost extension) was of 1 year, 6 month duration, until the study closed to recruitment.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Alprazolam</title>
          <description>Healthy male volunteers receiving drug and undergoing 1H-MRSI scanning
Alprazolam: Alprazolam, gel-capsule, 1mg, single-dose, 1-day</description>
        </group>
        <group group_id="E2">
          <title>Dextroamphetamine</title>
          <description>Healthy male volunteers receiving drug and undergoing 1H-MRSI scanning
Dextroamphetamine: Dextroamphetamine, gel-capsule, 20mg, single-dose, 1-day</description>
        </group>
        <group group_id="E3">
          <title>Placebo</title>
          <description>Healthy male volunteers receiving drug and undergoing 1H-MRSI scanning
Placebo, single-dose, 1-day</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. J. Eric Jensen</name_or_title>
      <organization>McLean Hospital</organization>
      <phone>617-855-3366</phone>
      <email>ejensen@mclean.harvard.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

